← All trials
NCT06288360
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 12, 2024
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 12, 2030
- First posted
- Mar 1, 2024
- Last posted
- Oct 30, 2024
- Enrollment
- 40
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Huazhong University of Science and TechnologyLead sponsor
- Guangxi Medical UniversityCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Central South UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Huazhong University of Science and TechnologySponsor investigator
- Capital Medical UniversityCollaborator
- Shengjing HospitalCollaborator
- Tianjin Medical UniversityCollaborator
- Sichuan UniversityCollaborator
- Shandong UniversityCollaborator
- Zhejiang UniversityCollaborator
- Anhui Medical UniversityCollaborator
- Gansu Provincial Maternity and Child-Care HospitalCollaborator
- Huazhong University of Science and TechnologyOfficial
- People's Liberation Army of ChinaCollaborator
- University of Electronic Science and Technology of ChinaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.